Error-Proof Entry, Expert Positioning, and Exploding Growth in Embryonic Stem Cell Products
Market Report, June 2012
Format: PDF; 126 pages
How to profit from emerging opportunities in
embryonic stem cell research products
Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. Human embryonic stem cells are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body.
Human embryonic stem cells were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research.
Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. Of particular interest to the medical community is the potential for use of hESCs to heal tissues with naturally limited capacity for renewal, such as the human heart, liver and brain. However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for companies seeking to develop new products.
This market research report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market, from collaborating with WARF to less costly alternatives - such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species.
The potential medical advances made possible from the use of human embryonic stem cells (hESC) are huge. These stem cells are able to develop into any of over 200 different cell types. So it’s no surprise that the scientific research community is enthusiastically exploring all possibilities.
And where there is significant and growing interest from scientists, there is an opportunity for a company like yours to increase revenue from supplying stem cell products. There is no doubt it’s an exciting market in which to expand your product range. But with embryonic stem cells there are serious market entry barriers to consider – namely a complex intellectual property scene.
In summary, this report reveals market intelligence, guidance, and strategies for the embryonic stem cell product market.
- Key advances in embryonic stem cell research
- A breakdown of embryonic stem cell research applications, including shared priorities and priorities by segment
- Embryonic stem cell patent restrictions and opportunties
- Historical and future growth projections for the embryonic stem cell market
- Competitive analysis of providers of embryonic stem cell research tools
- Overview of specialty pharma companies developing embryonic stem cell therapies
- Overview of toxicology testing legislation impacting use of embryonic stem cells in toxicology applications
- A breakdown of embryonic stem cell research product categories
- Suggestions for novel embryonic stem cell research products, including cells, kits, assays, media and reagents
- Guidance for companies that wish to offer high-demand embryonic stem cell products
- And much more
This report will help you understand the market entry challenges you face and give you the expert advice to overcome them. Couple this with market leading commercial intelligence data and this report is a must have if you’re looking to outcompete your rivals in this expanding and highly profitable market.
Additional Product Details
View Table of Contents
"Test-Drive" The Product For Yourself
Download Free Product Sample 1
Download Free Product Sample 2
Download Free Product Sample 3
* All major international currencies accepted.
** Report delivered by email in PDF format / Hard copy sent by post.
*** All purchases backed by BioInformant's 60-Day Money Back Guarantee.
(Phone) 703-859-7617 email@example.com (Fax) 614-352-2369
Copyright © 2012 BioInformant Worldwide, L.L.C. All rights reserved.